ABOUT THE ADVENTURE GENE THERAPY TRIAL FOR ADULT CAH

Adrenas is the only company currently working to develop a gene therapy that may enable people living with congenital adrenal hyperplasia (CAH) to produce the hormones that the body needs to function properly.

The specific goal of the Adrenas ADventure trial is to provide a safe and effective gene therapy treatment that may correct hormone imbalances in adults living with classic CAH due to 21-hydroxylase deficiency. The trial will evaluate the safety, tolerability and optimal dose range of the investigational gene therapy. The ADventure trial is being conducted in the United States and Australia.

You may be eligible for the ADventure Gene Therapy Trial for Adult Classic CAH if:
Adrenas

You are 18 years of age or older

Adrenas

You have a diagnosis of classic CAH (simple-virilizing or salt-wasting)

Other eligibility criteria apply, and you may complete a Pre-screening Study to see whether you may be able to take part.

For more information about ADventure including additional eligibility criteria, please visit https://clinicaltrials.gov/ct2/show/NCT04783181.

During the clinical trial, the Adrenas investigational gene therapy will be administered in a single intravenous dose.

There is no cost for taking part in the ADventure Gene Therapy Trial for CAH, or during the Pre-screening Study or Long-term Follow-up as described below. Travel and trial-related expenses will be paid for by Adrenas.

Click “NEXT” to answer the first set of pre-screening questions

NEED HELP?


For questions related to the Adrenas clinical program, please email: clinicaltrials@adrenastx.com

For Frequently Asked Questions about ADventure and the ADvance-CAH program click here